Arndt Vogel

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin et al. · The Lancet · 2018 · 5.4K citations · Full text

Medicine, Oncology, Pharmacology +12

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Medicine, Oncology, Pharmacology +11

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K. Abou‐Alfa, Vaibhav Sahai, Antoine Hollebecque et al. · The Lancet Oncology · 2020 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +11

Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Florian Lordick, Fátima Carneiro, Stefano Cascinu et al. · Annals of Oncology · 2022 · 1.4K citations · Full text

Medicine, Oncology, Surgery +14

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al. · Nature · 2021 · 1.2K citations · Full text

Life Sciences, Immunology, Oncology +17